Who are Trevi Therapeutics, Inc.'s main suppliers?

Trevi Therapeutics, Inc. (TRVI) key suppliers include: CONTRACT-MANUFACTURERS, CROS, CELG-RI, CELG-RI, GSK plc and 7 more. View the full supplier network at chainsifter.com/chain/TRVI.

Who are Trevi Therapeutics, Inc.'s major customers?

Trevi Therapeutics, Inc. (TRVI) key customers include: CELG-RI, CELG-RI, GSK plc, GSK plc, Merck & Co., Inc. and 5 more. View the full customer network at chainsifter.com/chain/TRVI.

What sector is Trevi Therapeutics, Inc. in?

Trevi Therapeutics, Inc. (TRVI) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

TRVI Supply Chain: Trevi Therapeutics, Inc. Supplier List & 25 Relationships

12Suppliers

10Customers

3Debt Items

20Related Chains

Trevi Therapeutics, Inc. Suppliers

Ticker	Name	Confidence	Evidence
CONTRACT-MANUFACTURERS	CONTRACT-MANUFACTURERS	90%	A significant portion of the Company’s development activities are outsourced to third parties under agreements, including with CROs and contract manufacturers in connection with the production of cli…
CROS	CROS	90%	A significant portion of the Company’s development activities are outsourced to third parties under agreements, including with CROs and contract manufacturers in connection with the production of cli…
CELG-RI	CELG-RI	72%	inuing voluntary cooperation in other areas. Individual European Union Member States will continue to be responsible for assessing non-clinical (e.g., economic, social and ethical) aspects of health …
CELG-RI	CELG-RI	72%	Reciprocal relationship from CELG-RI graph: Reciprocal relationship from TRVI graph: inuing voluntary cooperation in other areas. Individual European Union Member States will continue to be responsib…
GSK	GSK plc	72%	Reciprocal relationship from GSK graph: Reciprocal relationship from TRVI graph: Reciprocal relationship from GSK graph: Reciprocal relationship from TRVI graph: ions, they may separately regulate dr…
GSK	GSK plc	72%	ions, they may separately regulate drugs as well. While some states automatically classify a drug when the DEA does so, in other states there must be rulemaking or a legislative action. Regulatory au…
MRK	Merck & Co., Inc.	72%	Reciprocal relationship from MRK graph: Reciprocal relationship from TRVI graph: Reciprocal relationship from MRK graph: Reciprocal relationship from TRVI graph: Reciprocal relationship from MRK grap…
MRK	Merck & Co., Inc.	72%	ions, they may separately regulate drugs as well. While some states automatically classify a drug when the DEA does so, in other states there must be rulemaking or a legislative action. Regulatory au…
ORANY	ORANY	72%	Reciprocal relationship from ORANY graph: Reciprocal relationship from TRVI graph: Reciprocal relationship from ORANY graph: Reciprocal relationship from TRVI graph: r commercial scale manufacturing …
ORANY	ORANY	72%	r commercial scale manufacturing capabilities. Although we rely on contract manufacturers, we have personnel with experience to oversee our relationships with contract manufacturers. Haduvio is manuf…
SNYNF	Sanofi	72%	Reciprocal relationship from SNYNF graph: Reciprocal relationship from TRVI graph: ity of these patents. Even if we pursue such enforcement or defense, we will require the cooperation of our licensor…
SNYNF	Sanofi	72%	ity of these patents. Even if we pursue such enforcement or defense, we will require the cooperation of our licensors and cannot guarantee that we would receive it and on what terms. We cannot be cer…

Trevi Therapeutics, Inc. Customers

Ticker	Name	Confidence	Evidence
CELG-RI	CELG-RI	72%	Reciprocal relationship from CELG-RI graph: Reciprocal relationship from TRVI graph: Reciprocal relationship from CELG-RI graph: Reciprocal relationship from TRVI graph: Reciprocal relationship from …
CELG-RI	CELG-RI	72%	inuing voluntary cooperation in other areas. Individual European Union Member States will continue to be responsible for assessing non-clinical (e.g., economic, social and ethical) aspects of health …
GSK	GSK plc	72%	Reciprocal relationship from GSK graph: Reciprocal relationship from TRVI graph: ions, they may separately regulate drugs as well. While some states automatically classify a drug when the DEA does so…
GSK	GSK plc	72%	ions, they may separately regulate drugs as well. While some states automatically classify a drug when the DEA does so, in other states there must be rulemaking or a legislative action. Regulatory au…
MRK	Merck & Co., Inc.	72%	Reciprocal relationship from MRK graph: Reciprocal relationship from TRVI graph: ions, they may separately regulate drugs as well. While some states automatically classify a drug when the DEA does so…
MRK	Merck & Co., Inc.	72%	ions, they may separately regulate drugs as well. While some states automatically classify a drug when the DEA does so, in other states there must be rulemaking or a legislative action. Regulatory au…
ORANY	ORANY	72%	r commercial scale manufacturing capabilities. Although we rely on contract manufacturers, we have personnel with experience to oversee our relationships with contract manufacturers. Haduvio is manuf…
ORANY	ORANY	72%	Reciprocal relationship from ORANY graph: Reciprocal relationship from TRVI graph: Reciprocal relationship from ORANY graph: Reciprocal relationship from TRVI graph: Reciprocal relationship from ORAN…
SNYNF	Sanofi	72%	Reciprocal relationship from SNYNF graph: Reciprocal relationship from TRVI graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from TRVI graph: ity of these patents. Even if we …
SNYNF	Sanofi	72%	ity of these patents. Even if we pursue such enforcement or defense, we will require the cooperation of our licensors and cannot guarantee that we would receive it and on what terms. We cannot be cer…

Trevi Therapeutics, Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
TRVI-DEBT	Debt stack $682,000	90%	Market cache reports total debt of $682,000.
TRVI-DEBT-13114	Warrants outstanding: 10757000	90%	xbrl warrant detail from xbrl 2025-12-31.
TRVI-DEBT-13115	Xbrl Convertible	90%	xbrl convertible detail from xbrl 2019-12-31.

Trevi Therapeutics, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Trevi Therapeutics, Inc..

Trevi Therapeutics, Inc. Ownership

Holder	Name	Confidence	Evidence
TRVI-OWNER-NEA-MANAGEMENT-COMPANY-LLC	NEA Management Company, LLC	90%	13F overlay lists NEA Management Company, LLC as top holder; 201 tracked holders.

Trevi Therapeutics, Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops	Relationship Types
ORANY	ORANGE	100.00	1	['customer', 'supplier']
GSK	GSK plc	100.00	1	['customer', 'supplier']
MRK	Merck & Co., Inc.	100.00	1	['customer', 'supplier']
CELG-RI	BRISTOL MYERS SQUIBB CO	100.00	1	['customer', 'supplier']
SNYNF	Sanofi	100.00	1	['customer', 'supplier']
AMZE	Amaze Holdings, Inc.	50.00	2
ALXO	ALX Oncology Holdings Inc.	50.00	2
BLRX	BioLineRx Ltd.	50.00	2
AYTU	Aytu BioPharma, Inc.	50.00	2
CYTOF	Altamira Therapeutics Ltd.	50.00	2
CTMX	CytomX Therapeutics, Inc.	50.00	2
CTNM	Contineum Therapeutics, Inc.	50.00	2
D	Dominion Energy, Inc.	50.00	2
ANL	Adlai Nortye Ltd.	50.00	2
WHWK	Whitehawk Therapeutics, Inc.	50.00	2
DEO	Diageo plc	50.00	2
EXOZ	eXoZymes, Inc.	50.00	2
CPRX	Catalyst Pharmaceuticals, Inc.	50.00	2
BNBX	BNB Plus Corp.	50.00	2
DARE	Daré Bioscience, Inc.	50.00	2

Trevi Therapeutics, Inc. Supply Chain